Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1974 10
1975 5
1976 6
1977 4
1978 9
1979 7
1980 2
1983 2
1984 3
1985 1
1986 2
1987 6
1988 11
1989 6
1990 7
1991 7
1992 7
1993 16
1994 34
1995 26
1996 43
1997 41
1998 46
1999 59
2000 40
2001 36
2002 24
2003 43
2004 60
2005 38
2006 40
2007 35
2008 31
2009 42
2010 27
2011 26
2012 23
2013 18
2014 12
2015 12
2016 18
2017 20
2018 21
2019 12
2020 13
2021 9
2022 7
2023 3
2024 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

915 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of Acute Followed by Maintenance ECT vs Clozapine on Psychopathology and Regional Cerebral Blood Flow in Treatment-Resistant Schizophrenia: A Randomized Controlled Trial.
Mishra BR, Agrawal K, Biswas T, Mohapatra D, Nath S, Maiti R. Mishra BR, et al. Schizophr Bull. 2022 Jun 21;48(4):814-825. doi: 10.1093/schbul/sbac027. Schizophr Bull. 2022. PMID: 35556138 Free PMC article. Clinical Trial.
BACKGROUND AND HYPOTHESIS: In treatment-resistant schizophrenia (TRS), Clozapine is only approved treatment with undesirable side-effects, warranting better alternatives. Our hypothesis is acute followed by maintenance Electroconvulsive Therapy (M-ECT) will be comparable i …
BACKGROUND AND HYPOTHESIS: In treatment-resistant schizophrenia (TRS), Clozapine is only approved treatment with undesirable side-eff …
Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial.
Zhu MH, Liu ZJ, Hu QY, Yang JY, Jin Y, Zhu N, Huang Y, Shi DH, Liu MJ, Tan HY, Zhao L, Lv QY, Yi ZH, Wu FC, Li ZZ. Zhu MH, et al. Mil Med Res. 2022 Oct 18;9(1):59. doi: 10.1186/s40779-022-00420-0. Mil Med Res. 2022. PMID: 36253804 Free PMC article. Clinical Trial.
BACKGROUND: Although clozapine is an effective option for treatment-resistant schizophrenia (TRS), there are still 1/3 to 1/2 of TRS patients who do not respond to clozapine. The main purpose of this randomized, double-blind, placebo-controlled trial was to explore …
BACKGROUND: Although clozapine is an effective option for treatment-resistant schizophrenia (TRS), there are still 1/3 to 1/2 of TRS …
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.
Kane J, Honigfeld G, Singer J, Meltzer H. Kane J, et al. Arch Gen Psychiatry. 1988 Sep;45(9):789-96. doi: 10.1001/archpsyc.1988.01800330013001. Arch Gen Psychiatry. 1988. PMID: 3046553 Clinical Trial.
This report describes a multicenter clinical trial to assess clozapine's efficacy in the treatment of patients who are refractory to neuroleptics. DSM-III schizophrenics who had failed to respond to at least three different neuroleptics underwent a prospective, sing …
This report describes a multicenter clinical trial to assess clozapine's efficacy in the treatment of patients who are refract …
Randomized, double-blind, sham-controlled trial to evaluate the efficacy and tolerability of electroconvulsive therapy in patients with clozapine-resistant schizophrenia.
Melzer-Ribeiro DL, Napolitano IC, Leite SA, Alencar de Souza JA, Vizzotto ADB, Di Sarno ES, Fortes M, Gomes ML, de Oliveira GM, Avrichir BS, Talib LL, Correll CU, Elkis H. Melzer-Ribeiro DL, et al. Schizophr Res. 2024 Jun;268:252-260. doi: 10.1016/j.schres.2023.11.009. Epub 2023 Dec 26. Schizophr Res. 2024. PMID: 38151432 Clinical Trial.
There is no established treatment for patients with clozapine-resistant schizophrenia (CRS). Clozapine augmentation strategies with antipsychotics or others substances are effective in comparison with placebo while and Electroconvulsive therapy (ECT) showed to be ef …
There is no established treatment for patients with clozapine-resistant schizophrenia (CRS). Clozapine augmentation strategies …
Update on the clinical efficacy and side effects of clozapine.
Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B. Safferman A, et al. Schizophr Bull. 1991;17(2):247-61. doi: 10.1093/schbul/17.2.247. Schizophr Bull. 1991. PMID: 1882209 Review.
Clozapine (CLOZ) is an atypical antipsychotic drug being used with increasing frequency throughout the world and has recently been commercially marketed in the United States. ...
Clozapine (CLOZ) is an atypical antipsychotic drug being used with increasing frequency throughout the world and has recently been co …
Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study.
Lindenmayer JP, Iskander A, Park M, Apergi FS, Czobor P, Smith R, Allen D. Lindenmayer JP, et al. J Clin Psychiatry. 1998 Oct;59(10):521-7. doi: 10.4088/jcp.v59n1005. J Clin Psychiatry. 1998. PMID: 9818633 Clinical Trial.
However, clozapine was numerically superior to risperidone on PANSS total scores and PANSS positive, negative, excitement, and cognitive factors. ...Patients taking clozapine showed a gradual improvement that occurred over the entire length of the trial. ...
However, clozapine was numerically superior to risperidone on PANSS total scores and PANSS positive, negative, excitement, and cognit …
Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia.
Chong SA, Tan CH, Khoo YM, Lee HS, Wong KE, Ngui F, Winslow M. Chong SA, et al. Ther Drug Monit. 1997 Apr;19(2):219-23. doi: 10.1097/00007691-199704000-00018. Ther Drug Monit. 1997. PMID: 9108654 Clinical Trial.
The relationships between clozapine dosages, plasma concentrations, and clinical responses in Chinese schizophrenics were studied. ...There was wide interindividual variation in the plasma clozapine concentrations. Compared with other studies, the plasma clozapin …
The relationships between clozapine dosages, plasma concentrations, and clinical responses in Chinese schizophrenics were studied. .. …
Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations.
Llorca PM, Lancon C, Disdier B, Farisse J, Sapin C, Auquier P. Llorca PM, et al. J Psychiatry Neurosci. 2002 Jan;27(1):30-7. J Psychiatry Neurosci. 2002. PMID: 11836974 Free PMC article. Clinical Trial.
OBJECTIVE: To assess the relation between plasma concentrations of clozapine and its 2 main metabolites desmethyl clozapine and clozapine N-oxide, and clinical change in a sample of inpatients with schizophrenia who were resistant to conventional neuroleptics …
OBJECTIVE: To assess the relation between plasma concentrations of clozapine and its 2 main metabolites desmethyl clozapine an …
Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine.
Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH. Pickar D, et al. Arch Gen Psychiatry. 1992 May;49(5):345-53. doi: 10.1001/archpsyc.1992.01820050009001. Arch Gen Psychiatry. 1992. PMID: 1375019 Clinical Trial.
A striking biologic difference between clozapine and fluphenazine was clozapine's enhancement of indexes of noradrenergic activity. Superior clozapine response was predicted by low ratios of cerebrospinal fluid homovanillic acid to 5-hydroxyindoleaceti …
A striking biologic difference between clozapine and fluphenazine was clozapine's enhancement of indexes of noradrenerg …
ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
Jaquenoud Sirot E, Knezevic B, Morena GP, Harenberg S, Oneda B, Crettol S, Ansermot N, Baumann P, Eap CB. Jaquenoud Sirot E, et al. J Clin Psychopharmacol. 2009 Aug;29(4):319-26. doi: 10.1097/JCP.0b013e3181acc372. J Clin Psychopharmacol. 2009. PMID: 19593168 Clinical Trial.
To examine the genetic factors influencing clozapine kinetics in vivo, 75 patients treated with clozapine were genotyped for CYPs and ABCB1 polymorphisms and phenotyped for CYP1A2 and CYP3A activity. ...Carriers of the ABCB1 3435TT genotype had a 1.6-fold higher …
To examine the genetic factors influencing clozapine kinetics in vivo, 75 patients treated with clozapine were genotyped for C …
915 results